XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
Total
Common Stock
Additional Paid-In Capital
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   1,809,593    
Beginning balance at Dec. 31, 2021 $ 38,722,985 $ 181 $ 70,919,996 $ (32,197,192)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Common stock issued for in-process research and development technology (in shares)   40,000    
Common stock issued for in-process research and development technology 487,900 $ 4 487,896  
Equity-based compensation expense (in shares)   18,215    
Equity-based compensation expense 313,903 $ 2 313,901  
Net loss (6,109,225)     (6,109,225)
Ending balance (in shares) at Mar. 31, 2022   1,867,808    
Ending balance at Mar. 31, 2022 33,415,563 $ 187 71,721,793 (38,306,417)
Beginning balance (in shares) at Dec. 31, 2022   2,255,899    
Beginning balance at Dec. 31, 2022 10,384,608 $ 225 74,189,531 (63,805,148)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Issuance of equity securities, net (in shares)   142,499    
Issuance of equity securities, net 311,681 $ 14 311,667  
Equity-based compensation expense (in shares)   69,899    
Equity-based compensation expense 203,345 $ 7 203,338  
Net loss (5,340,773)     (5,340,773)
Ending balance (in shares) at Mar. 31, 2023   2,468,297    
Ending balance at Mar. 31, 2023 $ 5,558,861 $ 246 $ 74,704,536 $ (69,145,921)